20.08.2014 - Biopharmaceutical contract manufacturer Fujifilm Diosynth Biotechnologies is expanding its cell culture manufacturing capacity further with a new 2,000l single-use bioreactor at the company’s site in Billingham, UK.
The site currently operates 1,000l single-use bioreactors with 250l to 1,000l operating volumes, with an additional 200l single-use bioreactor. The new bioreactor is expected to be operational by January 2015. Another similar reactor will be installed by November 2014 in Fujifilm Diosynth’s US-American site Research Triangle Park.
"The addition of these two new bioreactors will meet the demand we are seeing for a 2,000l platform, and offer a cost-effective, low-risk route to market through 'scaling-out' from early phase to commercial manufacture," says Steve Bagshaw, Chief Executive Officer, Fujifilm Diosynth Biotechnologies. He added: "Having identical single-use operations on both sides of the Atlantic offers our customers flexibility and easy access to global markets."
08.08.2014 Boehringer Ingelheim is walking away from Swedish Orexo's prostaglandin inhibition project OX-MPI. Germany's largest researching pharmaceutical company had been responsible for the project's research and development since 2005.